FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:64-66 January 6, 1994 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Packer, M. Related Article Related Article by Feldman, A. M. PubMed Citation

To the Editor: In the report by Feldman et al. (July 15 issue)¹ we are concerned about the lack of agreement between the results of the two doses used in the trial. When the study was designed, it seemed plausible that the 120-mg dose would be more effective than the 60-mg dose. However, the opposite was found. We think it is important to combine the mortality data for the 87 patients receiving the higher dose of vesnarinone with those for the 239 patients receiving the lower dose, in addition to the analyses presented in the article. When this is done, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• O'Shaughnessy, K. M., Fu, B., Ferraro, F., Lewis, I., Downing, S., Morris, N. H. (1999). Factor V Leiden and Thermolabile Methylenetetrahydrofolate Reductase Gene Variants in an East Anglian Preeclampsia Cohort. Hypertension 33: 1338-1341 [Abstract] [Full Text]